Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC).

British Journal of Haematology
Pau AbrisquetaF Bosch

Abstract

Richter syndrome (RS) is an uncommon evolution of chronic lymphocytic leukaemia (CLL) with a dismal prognosis. Clinical-biological features predicting outcome and best therapeutic approach for these patients remain to be established. In this study, 128 patients with RS, including 112 diffuse large B-cell lymphoma (DLBCL)-type RS, 15 Hodgkin lymphoma (HL)-type RS, and one plasmablastic lymphoma, were identified in 11 centres of the Spanish CLL Study Group (GELLC). The median overall survival (OS) was 5·9 months for DLBCL-type RS and 30·8 months for HL-type RS. Eastern Cooperative Oncology Group Performance Status, haemoglobin level, platelet count, serum lactate dehydrogenase and β2-microglobulin levels, tumour protein p53 (TP53) abnormalities in the CLL clone concomitant to RS, number of prior therapies, and clonal relationship between CLL and RS, were associated with OS in patients with DLBCL-type RS. A platelet count of <100 × 109 /l, prior CLL therapy (0 vs. ≥1), and presence of TP53 alterations maintained an independent prognostic impact in the multivariate analysis. Patients without any of these factors had a better clinical outcome, with a median OS of 75·3 months, while patients with one or two or more of these factors p...Continue Reading

References

May 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Apostolia-Maria TsimberidouMichael J Keating
Aug 12, 2006·Cancer·Apostolia-Maria TsimberidouMichael J Keating
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Apostolia M TsimberidouMichael J Keating
May 22, 2008·British Journal of Haematology·Davide RossiGianluca Gaidano
Jun 11, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Davide RossiGianluca Gaidano
Jul 3, 2013·Clinical Lymphoma, Myeloma & Leukemia·Apostolia M TsimberidouUNKNOWN Chronic Lymphocytic Leukemia Research Consortium
Oct 16, 2013·The Journal of Experimental Medicine·Giulia FabbriRiccardo Dalla-Favera
Sep 10, 2014·American Journal of Hematology·Petra LangerbeinsBarbara Eichhorst
Mar 7, 2015·Blood·Mazie TsangSameer A Parikh
Jul 5, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jessica El-Asmar, Mohamed A Kharfan-Dabaja
Jan 18, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew S DavidsJohn F Gerecitano
Jul 18, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cameron J TurtleDavid G Maloney
Nov 12, 2017·Clinical Lymphoma, Myeloma & Leukemia·Mohamed A Kharfan-DabajaJulio C Chavez

❮ Previous
Next ❯

Citations

May 19, 2020·British Journal of Haematology·Toby A Eyre
Feb 14, 2021·Current Oncology Reports·Adalgisa Condoluci, Davide Rossi
Mar 30, 2021·Blood Reviews·Anna PetrackovaEva Kriegova
Jun 28, 2021·Hematology/oncology Clinics of North America·Wei Ding
Oct 5, 2021·British Journal of Haematology·Toby A EyreUNKNOWN Haemato-Oncology Task Force of the British Society for Haematology
Nov 18, 2021·Blood·Matthew S DavidsJennifer R Brown

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.